IN2014MN02539A - - Google Patents
Info
- Publication number
- IN2014MN02539A IN2014MN02539A IN2539MUN2014A IN2014MN02539A IN 2014MN02539 A IN2014MN02539 A IN 2014MN02539A IN 2539MUN2014 A IN2539MUN2014 A IN 2539MUN2014A IN 2014MN02539 A IN2014MN02539 A IN 2014MN02539A
- Authority
- IN
- India
- Prior art keywords
- features
- vivo
- favorable
- analogues
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000002349 favourable effect Effects 0.000 abstract 2
- 238000001727 in vivo Methods 0.000 abstract 2
- 150000002632 lipids Chemical class 0.000 abstract 2
- 230000009385 viral infection Effects 0.000 abstract 2
- 102000004895 Lipoproteins Human genes 0.000 abstract 1
- 108090001030 Lipoproteins Proteins 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 150000001841 cholesterols Chemical class 0.000 abstract 1
- 239000003925 fat Substances 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 238000010348 incorporation Methods 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 239000003921 oil Substances 0.000 abstract 1
- 210000003463 organelle Anatomy 0.000 abstract 1
- 238000005192 partition Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 150000003611 tocopherol derivatives Chemical class 0.000 abstract 1
- 125000002640 tocopherol group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
- C07H5/06—Aminosugars
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261656265P | 2012-06-06 | 2012-06-06 | |
| PCT/US2013/044285 WO2013184780A1 (en) | 2012-06-06 | 2013-06-05 | Novel iminosugars and their applications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN02539A true IN2014MN02539A (OSRAM) | 2015-07-24 |
Family
ID=49712581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2539MUN2014 IN2014MN02539A (OSRAM) | 2012-06-06 | 2013-06-05 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8921568B2 (OSRAM) |
| EP (1) | EP2858642A4 (OSRAM) |
| JP (1) | JP2015518896A (OSRAM) |
| KR (1) | KR20150035767A (OSRAM) |
| CN (1) | CN104703597A (OSRAM) |
| CA (1) | CA2875975A1 (OSRAM) |
| IN (1) | IN2014MN02539A (OSRAM) |
| WO (1) | WO2013184780A1 (OSRAM) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113425720A (zh) * | 2020-04-03 | 2021-09-24 | 深圳前海诺贝尔奖科学家技术转移转化有限公司 | 亚胺糖化合物在制备抗SARS-CoV-2病毒的药物中的用途 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6011902B2 (ja) * | 1979-12-27 | 1985-03-28 | 日本新薬株式会社 | モラノリンの誘導体 |
| DE3007078A1 (de) * | 1980-02-26 | 1981-09-10 | Bayer Ag, 5090 Leverkusen | Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel sowie in der tierernaehrung |
| IL128036A (en) * | 1996-07-15 | 2005-08-31 | Univ Amsterdam | Deoxynojirimycin derivatives comprising a polyclic alcohol group, pharmaceutical composition comprising a deoxynojirimycin derivative and uses thereof |
| US20030100532A1 (en) | 1997-02-14 | 2003-05-29 | Gary S. Jacob | Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections |
| US6465487B1 (en) | 1997-12-11 | 2002-10-15 | Synergy Pharmaceuticals, Inc. | Inhibition of membrane-associated viral replication |
| US6465488B1 (en) | 1997-12-11 | 2002-10-15 | Chancellor, Masters & Scholars Of The University Of Oxford | Inhibition of glycolipid biosynthesis |
| US6689759B1 (en) | 1998-02-12 | 2004-02-10 | G. D. Searle & Co. | Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy |
| EP1061922B9 (en) | 1998-02-12 | 2007-03-07 | United Therapeutics Corporation | Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections |
| JP2002536407A (ja) | 1999-02-12 | 2002-10-29 | ジー・ディー・サール・アンド・カンパニー | 肝炎ウィルス感染の治療のための置換−１，５−ジデオキシ−１，５−イミノ−ｄ−グルシトール化合物の使用 |
| US7256005B2 (en) | 1999-08-10 | 2007-08-14 | The Chancellor, Masters And Scholars Of The University Of Oxford | Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity |
| US7816560B1 (en) | 1999-08-10 | 2010-10-19 | Thomas Jefferson University | Long chain n-alkyl compounds and oxa-derivatives thereof |
| CN1243000C (zh) | 2000-02-11 | 2006-02-22 | 研究发展基金会 | 生育酚、生育三烯酚、其它苯并二氢吡喃和侧链衍生物,及其用途 |
| EP1261339A1 (en) * | 2000-02-14 | 2002-12-04 | Pharmacia Corporation | Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections |
| JP2006515577A (ja) | 2002-09-23 | 2006-06-01 | ザ・チャンセラー，マスターズ・アンド・スカラーズ・オヴ・ザ・ユニヴァーシティ・オヴ・オックスフォード | イオンチャネル活性を阻害するためのイミノ糖誘導体の使用 |
| CA2580584C (en) * | 2003-09-19 | 2015-07-28 | Galileo Pharmaceuticals, Inc. | Use of alpha-tocotrienol for treatment of mitochondrial diseases |
| NZ550945A (en) * | 2004-05-04 | 2010-04-30 | Academia Sinica | Anti-coronavirus compounds |
| KR100611931B1 (ko) * | 2004-09-02 | 2006-08-11 | 강경태 | 광학활성 알콕시알콜 화합물, 이로부터 유도되는 광학활성1,3-페닐렌-비스[4-(4-알콕시)페닐이미노메틸]벤조에이트화합물 및 이들의 제조방법 |
| WO2006107936A1 (en) * | 2005-04-04 | 2006-10-12 | Pontificia Universidad Catolica De Chile | The use of ezetimibe in the prevention and treatment of cholesterol gallstones |
| WO2007140184A2 (en) | 2006-05-24 | 2007-12-06 | United Therapeutics Corporation | Deoxynojirimycin and d-arabinitol analogs and methods of using |
| EP2049126A2 (en) | 2006-08-02 | 2009-04-22 | United Therapeutics Corporation | Liposome treatment of viral infections |
| WO2009118658A2 (en) | 2008-03-26 | 2009-10-01 | University Of Oxford | Endoplasmic reticulum targeting liposomes |
| US9040488B2 (en) * | 2008-09-02 | 2015-05-26 | Baruch S. Blumberg Institute | Imino sugar derivatives demonstrate potent antiviral activity and reduced toxicity |
| CN106420740A (zh) | 2009-02-23 | 2017-02-22 | 伊莫根特病毒学有限责任公司 | 亚氨基糖以及治疗病毒性疾病的方法 |
| ES2562635T3 (es) | 2009-02-24 | 2016-03-07 | United Therapeutics Corporation | Iminoazúcares y métodos de tratamiento de infecciones producidas por arenavirus |
| EP2410989A2 (en) | 2009-03-27 | 2012-02-01 | The Chancellor, Masters and Scholars of the University of Oxford | Cholesterol level lowering liposomes |
| US8426445B2 (en) | 2009-06-12 | 2013-04-23 | United Therapeutics Corporation | Iminosugars and methods of treating bunyaviral and togaviral diseases |
| EP2473482B1 (en) | 2009-09-04 | 2014-03-05 | United Therapeutics Corporation | Methods of treating orthomyxoviral infections |
| WO2011028781A1 (en) | 2009-09-04 | 2011-03-10 | United Therapeutics Corporation | Methods of treating poxviral infections |
| CN102595895A (zh) | 2009-09-04 | 2012-07-18 | 联合治疗公司 | 亚氨基糖以及治疗丝状病毒性疾病的方法 |
| JP2013512945A (ja) | 2009-12-07 | 2013-04-18 | ザ チャンセラー，マスターズ アンド スカラーズ オブ ザ ユニバーシティ オブ オックスフォード | 破骨細胞生成および／または破骨細胞活性化の阻害における使用のためのｎ置換デオキシノジリマイシン化合物 |
-
2013
- 2013-06-05 IN IN2539MUN2014 patent/IN2014MN02539A/en unknown
- 2013-06-05 US US13/910,564 patent/US8921568B2/en not_active Expired - Fee Related
- 2013-06-05 EP EP13800188.8A patent/EP2858642A4/en not_active Withdrawn
- 2013-06-05 WO PCT/US2013/044285 patent/WO2013184780A1/en active Application Filing
- 2013-06-05 CA CA2875975A patent/CA2875975A1/en not_active Abandoned
- 2013-06-05 KR KR20147036446A patent/KR20150035767A/ko not_active Withdrawn
- 2013-06-05 CN CN201380041515.XA patent/CN104703597A/zh active Pending
- 2013-06-05 JP JP2015516166A patent/JP2015518896A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN104703597A (zh) | 2015-06-10 |
| US8921568B2 (en) | 2014-12-30 |
| JP2015518896A (ja) | 2015-07-06 |
| KR20150035767A (ko) | 2015-04-07 |
| WO2013184780A1 (en) | 2013-12-12 |
| CA2875975A1 (en) | 2013-12-12 |
| EP2858642A4 (en) | 2015-12-02 |
| EP2858642A1 (en) | 2015-04-15 |
| US20130331578A1 (en) | 2013-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201591662A1 (ru) | Липиды и липидные композиции для доставки активных агентов | |
| NZ732777A (en) | Ionizable cationic lipid for rna delivery | |
| MX392812B (es) | Lipidos cationicos de trialquilo y metodos de uso de los mismos. | |
| EA201201343A1 (ru) | Производные 4-аминопиримидина и их действующее вещество как антагонисты аденозинового рецептора а | |
| CR20130617A (es) | Derivados de piridin-2(1h)-ona útiles como medicamentos para el tratamiento de trastornos mieloproliferativos, rechazo de trasplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias | |
| PH12015501074A1 (en) | Triazolopyrazine | |
| PH12015501385A1 (en) | Autotaxin inhibitors | |
| FR2986002A1 (fr) | Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| MX341332B (es) | Lipidos biodegradables para la administracion de agentes activos. | |
| IN2014DN00277A (OSRAM) | ||
| EA201492112A1 (ru) | ЗАМЕЩЕННЫЕ 3,4-ДИГИДРО-2H-ПИРИДО[1,2-a]ПИРАЗИН-1,6-ДИОНОВЫЕ ПРОИЗВОДНЫЕ, ПРИМЕНИМЫЕ ДЛЯ ЛЕЧЕНИЯ (В ТОМ ЧИСЛЕ) БОЛЕЗНИ АЛЬЦГЕЙМЕРА | |
| TW200736234A (en) | Chemical compounds | |
| PH12013500152A1 (en) | New aminopyrazoloquinazolines | |
| PL3447061T3 (pl) | Farmaceutyczna formulacja zawierająca pochodną fosforoamidynianową 5-fluoro-2'-deoksyurydyny do zastosowania w leczeniu nowotworu | |
| NI201500013A (es) | Tratamiento de enfermedades inmuno - relacionadas e inflamatorias. | |
| FR2977486B1 (fr) | Compositions cosmetiques sous la forme d'emulsions eau-dans-huile comprenant un derive d'acide jasmonique | |
| EA201391265A1 (ru) | Амиды индолкарбоновых и бензимидазолкарбоновых кислот в качестве инсектицидов и акарицидов | |
| ME03750B (me) | Farmaceutska formulacija koja sadrži inozitol | |
| MX357759B (es) | Formulaciones y formas de dosificacion de fosfolipidos oxidados. | |
| ECSP099382A (es) | Sulfonamidas heterocíclicos que tienen actividad antagonista edg-i | |
| RU2016109986A (ru) | Композиция для подавления раковых заболеваний крови или метастазирования рака, содержащая в качестве активного ингредиента моноацетилдиглицеридное соединение | |
| IN2014DN01619A (OSRAM) | ||
| HK1216504A1 (zh) | 疾病的治療方法 | |
| IN2014MN02539A (OSRAM) | ||
| EP2815742A4 (en) | IMPROVED ADMINISTRATIVE FORM WITH EXTRACT FROM THE RINDER OF LIRIODENDRON TULIPIFERA AS AN ACTIVE SUBSTANCE |